Mayfield continues to expand its use of the groundbreaking GammaTile® targeted radiation technology to treat brain tumors, putting it among a distinguished roster of national health systems.
In recent months, Mayfield neurosurgeons have expanded the use of GammaTile to patients at TriHealth’s Good Samaritan Hospital. This enhanced access to innovative technology is another example of Mayfield leveraging its research and clinical expertise to benefit patients. Mayfield neurosurgeons who have performed the procedure include Dr. Vincent DiNapoli, Dr. Yair Gozal, Dr. George Mandybur and Dr. Christopher McPherson.
GammaTile therapy received regulatory clearance from the U.S. Food and Drug Administration for the treatment of recurrent brain tumors in July 2018. In January 2020, the FDA expanded indications to allow patients with newly diagnosed malignant brain tumors to receive the therapy. In February 2020, Dr. DiNapoli was the first neurosurgeon in the country to use targeted GammaTile therapy for patients with newly diagnosed malignant brain tumors at The Jewish Hospital-Mercy Health, where he is director of the Brain Tumor Center.
GT Medical Technologies has identified five health systems that earned a place on its roster of Elite Distinguished Brain Tumor Specialists by performing at least 10 GammaTile procedures in 2020: Memorial Sloan Kettering Cancer Center, M Health Fairview, HonorHealth Scottsdale Osborn Medical Center, NorthShore University HealthSystem and Mayfield Brain & Spine.
“GammaTile treatment for newly diagnosed brain tumors is a significant step forward for patients and an example of the benefits that focused neurosurgical research and clinical innovation can provide,” Dr. DiNapoli said. “The targeted radiation delivered by GammaTile will save lives and set the stage for further groundbreaking advances against brain tumors. At Mayfield, we are committed to that research and innovation and delighted to be colleagues with a distinguished roster of clinical providers.”
GammaTile therapy, marketed by GT Medical Technologies, is implanted in the final stages of brain tumor removal surgery and provides immediate radiation therapy to a highly targeted area. The small collagen tile is placed directly at the site of the tumor immediately after the tumor is removed to target residual tumor cells before they can replicate. Because the therapy is implanted at the end of surgery, patients treated with GammaTile therapy require no additional trips to the hospital or clinic for radiation therapy.